专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20220404336A1 COMPOSITIONS, METHODS AND USES FOR FREE FATTY ACID SCREENING OF CELLS AT SCALE 有权
公开(公告)号：US20220404336A1
公开(公告)日：2022-12-22
申请号：US17641683
申请日：2020-09-09
申请人： THE BROAD INSTITUTE, INC. , THE BRIGHAM & WOMEN'S HOSPITAL, INC. , PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人： Anna Greka , Nicolas Wieder , Juliana Coraor
IPC分类号： G01N33/50 , C07K14/765 , C07K1/107 , C12Q1/6883
摘要： The present disclosure relates to compositions and methods for the preparation and use of free fatty acids as crystals and in solution, optionally in array format, for assay of lipotoxicity and related effects (in certain cases, indicators of diseases or disorders, such as type II diabetes) in contacted cells. Identification and therapeutic targeting of high-value gene targets discovered via joint assessment of lipotoxicity/transcriptome data and genetic association study data are also provided.

2. 发明授权

US11160808B2 Compounds that enhance Atoh1 expression 有权
公开(公告)号：US11160808B2
公开(公告)日：2021-11-02
申请号：US16518788
申请日：2019-07-22
申请人： Massachusetts Eye & Ear Infirmary , The Brigham & Women's Hospital, Inc.
发明人： Albert Edge , Sang-Jun Jeon , Kathleen Seyb , Marcie Glicksman , Lixin Qiao , Gregory D. Cuny
IPC分类号： A61K31/5377 , A61K31/343 , A61K31/381 , A61K31/415 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/341 , A61K31/4184 , A61K9/00 , A61K31/353 , A61K31/4436 , A61K31/496 , A61K31/498 , A61K31/517 , A61K31/519 , A61K35/28 , A61K35/545 , A61K31/352 , A61K31/404 , A61K31/4155 , A61K31/4192 , A61K31/4365 , A61K31/437 , A61K31/44 , A61K31/4439
摘要： This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

3. 发明授权

US10406163B2 Compounds that enhance Atoh1 expression 有权
公开(公告)号：US10406163B2
公开(公告)日：2019-09-10
申请号：US15240303
申请日：2016-08-18
申请人： Massachusetts Eye & Ear Infirmary , The Brigham & Women s Hospital, Inc.
发明人： Albert Edge , Sang-Jun Jeon , Kathleen Seyb , Marcie Glicksman , Lixin Qiao , Gregory D. Cuny
IPC分类号： A61K31/5377 , A61K31/341 , A61K31/343 , A61K31/381 , A61K31/415 , A61K31/4184 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K9/00 , A61K31/353 , A61K31/4436 , A61K31/496 , A61K31/498 , A61K31/517 , A61K31/519 , A61K35/28 , A61K35/545 , A61K31/352 , A61K31/404 , A61K31/4155 , A61K31/4192 , A61K31/4365 , A61K31/437 , A61K31/44 , A61K31/4439
摘要： This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

4. 发明授权

US09939437B2 Genetically encoded biosensors 有权
公开(公告)号：US09939437B2
公开(公告)日：2018-04-10
申请号：US15664326
申请日：2017-07-31
申请人： Howard Hughes Medical Institute , The Brigham & Women's Hospital, Inc.
发明人： Jonathan S. Marvin , Loren Looger , Richard T. Lee , Eric Schreiter
IPC分类号： G01N33/557 , G01N33/68 , G01N33/58 , C07K14/195 , C07K14/245 , C07K14/435
CPC分类号： G01N33/557 , C07K14/195 , C07K14/245 , C07K14/43595 , C07K2319/20 , C07K2319/24 , C07K2319/60 , G01N33/582 , G01N33/68 , G01N33/6812 , G01N2400/00 , G01N2458/00
摘要： The present disclosure provides, inter alia, genetically encoded recombinant peptide biosensors comprising analyte-binding framework portions and signaling portions, wherein the signaling portions are present within the framework portions at sites or amino acid positions that undergo a conformational change upon interaction of the framework portion with an analyte.

5. 发明申请

US20130280258A1 PROGNOSTIC, DIAGNOSTIC, AND CANCER THERAPEUTIC USES OF FANCI AND FANCI MODULATING AGENTS 审中-公开
标题翻译： FANCI和FANCI调节剂的预防，诊断和癌症治疗用途
公开(公告)号：US20130280258A1
公开(公告)日：2013-10-24
申请号：US13413129
申请日：2012-03-06
申请人： Alan D. D'Andrea , Patrizia Vinciguerra , Stephen J. Elledge , Shuhei Matsuoka , Agata M. Smogorzewska , Kay O. Hofmann
发明人： Alan D. D'Andrea , Patrizia Vinciguerra , Stephen J. Elledge , Shuhei Matsuoka , Agata M. Smogorzewska , Kay O. Hofmann
IPC分类号： G01N33/68 , G01N33/50 , C07K16/18 , A61K31/713 , A61K45/06 , C12N9/10 , A61K39/395 , C12Q1/68 , C12N15/113
CPC分类号： G01N33/6875 , A61K31/713 , A61K39/3955 , A61K45/06 , C07K16/18 , C12N9/1088 , C12N15/113 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , G01N33/5011 , G01N33/574 , G01N33/57415 , G01N2500/10 , G01N2800/50
摘要： Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention identifies and characterizes the FANCI polypeptide as a vital component of the Fanconi anemia pathway and discloses inhibitors of FANCI and methods of using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.
摘要翻译：本文公开了用于治疗癌症的方法和组合物。特别地，本发明鉴定并表征FANCI多肽作为范可尼贫血途径的重要组成部分，并公开了FANCI的抑制剂及其使用方法。这样的抑制剂可用于抑制DNA损伤修复，并且可用于例如治疗癌症。

6. 发明授权

US08410053B2 Methods for treating autoimmune disorders, and reagents related thereto 有权
标题翻译：治疗自身免疫性疾病的方法及其相关试剂
公开(公告)号：US08410053B2
公开(公告)日：2013-04-02
申请号：US10496627
申请日：2002-11-26
申请人： William W. Bachovchin , Vijay K. Kuchroo
发明人： William W. Bachovchin , Vijay K. Kuchroo
IPC分类号： A61K38/00
CPC分类号： A61K31/40 , A61K31/401 , A61K31/69 , A61K38/005
摘要： The invention generally relates to improved methods for treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease.
摘要翻译：本发明一般涉及包括I型糖尿病，败血性休克，多发性硬化，炎性肠病（IBD）和克罗恩病的自身免疫性疾病的动物受试者（包括人）中的治疗或预防的改进方法。

7. 发明授权

US08232067B2 Disrupting FCRN-albumin interactions 有权
标题翻译：破坏FCRN-白蛋白相互作用
公开(公告)号：US08232067B2
公开(公告)日：2012-07-31
申请号：US13322983
申请日：2010-05-28
申请人： Richard S. Blumberg , Timothy T. C. Kuo
发明人： Richard S. Blumberg , Timothy T. C. Kuo
IPC分类号： G01N31/00 , G01N33/53
CPC分类号： C07K14/76 , C07K14/70535 , G01N33/566 , G01N2500/02
摘要： Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.
摘要翻译：本文提供了用于鉴定用于治疗受试者中结合白蛋白的化合物或分子的毒性作用的候选化合物的方法。所述方法包括鉴定抑制FcRn和白蛋白结合的测试化合物。

8. 发明申请

US20110280887A1 METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE 有权
标题翻译：心血管疾病诊断方法
公开(公告)号：US20110280887A1
公开(公告)日：2011-11-17
申请号：US13151012
申请日：2011-06-01
申请人： Richard T. Lee
发明人： Richard T. Lee
IPC分类号： A61K39/395 , A61P9/00
CPC分类号： G01N33/6869 , A61K45/06 , C12Q1/6883 , C12Q2600/136 , C12Q2600/158 , G01N33/5008 , G01N33/5023 , G01N33/5041 , G01N33/5061 , G01N33/5091 , G01N33/6887 , G01N33/6893 , G01N2333/7155 , G01N2800/2871 , G01N2800/32 , G01N2800/323 , G01N2800/324 , G01N2800/325 , G01N2800/52
摘要： This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
摘要翻译：本发明涉及用于诊断和治疗心血管病症的方法和组合物。更具体地，本发明涉及可用于诊断和/或治疗包括心脏肥大，心肌梗塞，中风，动脉硬化和心力衰竭的心血管疾病的分离的分子。

9. 发明申请

US20060104969A1 Compositions and methods for enhancing structural and functional nervous system reorganization and recovery 审中-公开
标题翻译：用于增强结构和功能性神经系统重组和恢复的组合物和方法
公开(公告)号：US20060104969A1
公开(公告)日：2006-05-18
申请号：US11205501
申请日：2005-08-16
申请人： Serkan Oray , Ania Majewska , Mriganka Sur , Yang Teng
发明人： Serkan Oray , Ania Majewska , Mriganka Sur , Yang Teng
IPC分类号： A61K38/48
CPC分类号： A61K38/49 , A61K33/14 , A61K33/30 , A61K33/42 , A61K38/484 , A61K45/06 , A61L27/54 , A61L2300/254 , A61L2300/412 , A61K2300/00
摘要： The present invention provides methods and compositions for enhancing recovery in a subject suffering from damage to the nervous system. In particular, the invention includes a method for promoting recovery and/or reorganization in the nervous system of a subject in need of enhancement of recovery and/or reorganization of the nervous system as a result of ischemic, hemorrhagic, neoplastic, degenerative, or traumatic damage by focally administering a composition comprising a proteolysis-enhancing agent such as tissue plasminogen activator (tPA), plasmin, or a PAI inhibitor to the nervous system of the subject. In some embodiments an additional active agent is also administered. The composition can be delivered using a variety of techniques including injection, via infusion pump, from an implantable microchip, or using a polymeric delivery vehicle. The composition can be administered, for example, to one or more subdivisions or areas of the brain, the spinal cord, or to one or more nerves or nerve tracts innervating diverse regions of the body. The invention also includes a drug delivery device for implantation into the nervous system to promote nervous system reorganization and/or recovery following ischemic, hemorrhagic, neoplastic, traumatic or degenerative damage, the drug delivery device comprising a biocompatible polymer and a proteolysis-enhancing agent such as tissue plasminogen activator (tPA), plasmin, or a PAI inhibitor, wherein the proteolysis-enhancing agent is released from the polymer in an amount effective to promote structural reorganization of the nervous system. In some embodiments the biocompatible polymer is a hydrogel.
摘要翻译：本发明提供用于增强患有神经系统损伤的受试者的恢复的方法和组合物。特别地，本发明包括促进需要增强神经系统的恢复和/或重组作为缺血性，出血性，肿瘤性，退行性或外伤性的结果的神经系统中的恢复和/或重组的方法。通过向受试者的神经系统照射施用包含蛋白水解增强剂如组织纤溶酶原激活剂（tPA），纤溶酶或PAI抑制剂的组合物的损伤。在一些实施方案中，还施用另外的活性剂。组合物可以使用各种技术递送，包括注射，通过输注泵，可植入微芯片，或使用聚合物递送载体。组合物可以例如施用于脑，脊髓的一个或多个细分或区域，或者一个或多个神经或神经束，其支配身体的不同区域。本发明还包括用于植入神经系统以促进缺血性，出血性，肿瘤性，创伤性或退行性损伤后的神经系统重组和/或恢复的药物递送装置，药物递送装置包含生物相容性聚合物和蛋白水解增强剂，例如作为组织纤溶酶原激活剂（tPA），纤溶酶或PAI抑制剂，其中蛋白水解增强剂以有效促进神经系统结构重组的量从聚合物中释放。在一些实施方案中，生物相容性聚合物是水凝胶。

10. 发明授权

US07012133B1 Antibodies to C-C chemokine Receptor 3 Protein 失效
标题翻译： C-C趋化因子受体3蛋白的抗体
公开(公告)号：US07012133B1
公开(公告)日：2006-03-14
申请号：US08963656
申请日：1997-11-03
申请人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
发明人： Craig J. Gerard , Norma P. Gerard , Charles R. Mackay , Paul D. Ponath , Theodore W. Post , Shixin Qin
IPC分类号： C07K16/00 , C12N15/63 , C12N15/00
CPC分类号： C07K16/2866 , A01K2217/05 , A61K38/00 , A61K47/642 , C07K14/7158 , C07K2317/76 , C07K2319/00 , C12N2799/026
摘要： The present invention relates to isolated and/or recombinant nucleic acids which encode a mammalian (e.g., human) receptor protein designated C—C Chemokine Receptor 3 (CKR-3) or Eos L2, and to proteins or polypeptides, referred to herein as isolated, recombinant mammalian CKR-3 receptors. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a receptor protein of the present invention or a portion thereof; to host cells comprising such constructs, useful for the production of recombinant CKR-3 receptors or polypeptides; and to antibodies reactive with the receptors, which are useful in research and diagnostic applications. Also provided are methods of use of the nucleic acids, proteins, and host cells to identify ligands, inhibitors (e.g., antagonists) or promoters (agonists) of receptor function. Administration of a compound which inhibits or promotes receptor function to an individual in need of therapy provides a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections. As a major leukocyte chemokine receptor present in leukocytes such as eosinophils and lymphocytes, the receptor provides a key target for drug screening and design.
摘要翻译：本发明涉及编码称为CC趋化因子受体3（CKR-3）或Eos L2的哺乳动物（例如，人）受体蛋白以及本文称为分离的重组体的蛋白质或多肽的分离和/或重组核酸哺乳动物CKR-3受体。本发明还涉及重组核酸构建体，其包含编码本发明的受体蛋白或其部分的核酸; 包含可用于产生重组CKR-3受体或多肽的包含此类构建体的宿主细胞; 以及与受体反应的抗体，其可用于研究和诊断应用。还提供了使用核酸，蛋白质和宿主细胞来鉴定受体功能的配体，抑制剂（例如拮抗剂）或启动子（激动剂）的方法。给予需要治疗的个体抑制或促进受体功能的化合物的施用提供了选择性调节白细胞功能的新方法，其可用于多种炎性和自身免疫疾病或用于治疗感染。作为白细胞如嗜酸性粒细胞和淋巴细胞中存在的主要白细胞趋化因子受体，该受体是药物筛选和设计的关键目标。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式